BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $45.99M rose 98.8% year over year, ahead of the +90.5% change in trailing-twelve-month operating expenses. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at +3360.1% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +98.8% holds above the trailing-twelve-month pace of +90.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$45.99M+6.0% QoQ
Last fiscal yearDec 2025
$145.82M+80.3% YoY
LTMMar 2026
$168.68M+90.5% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+98.8%——
1 year+80.3%——
3-year CAGR+3360.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
145.82M USD
Year-over-year change
+80.3%
4-year CAGR
+661.5%

Operating Expenses vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +90.5% is the 3rd highest of 10, against a peer median of +23.2%.
  • Over three fiscal years its annual growth of +3360.1% compares with a peer median of +28.4%.
BBOT Competitors
Operating Expenses for BBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$317.52M USD+142.5%+109.8%45.2%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$270.62M USD-24.2%+22.1%132.1%
XNCRXencor, Inc.LTM Jun 2026$261.54M USD+14.7%+83.3%249.1%
KODKodiak Sciences Inc.LTM Sep 2026$251.17M USD+16.0%-10.8%—
URGNUroGen Pharma Ltd.LTM Mar 2026$234.45M USD+23.2%+17.9%166.9%
ANABAnaptysBio, Inc.LTM Mar 2026$229.74M USD+420.0%+71.3%98.9%
TNGXTango Therapeutics, Inc.LTM Sep 2026$227.59M USD+29.2%+8.0%—
SEPNSepterna, Inc.LTM Sep 2026$169.24M USD+70.9%—175.8%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$168.68M USD+90.5%+3360.1%—
OCSOculis Holding AGLTM Mar 2026CHF 69.81M CHF-10.3%+34.7%13851.6%
Peer median (excluding BBOT) —+23.2%+28.4%166.9%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development0056.29M73.11M121.2M
Selling, General & Admin43.36K3.52K8.49M7.76M24.62M
Operating Expenses43.36K3.52K64.77M80.86M145.82M
Depreciation & Amortization74.33K3.52K92K208K610K
EBITDA(43.36K)(3.52K)(64.68M)(80.66M)(145.21M)
EBITDA Margin—————
Operating Income(43.36K)(3.52K)(64.77M)(80.86M)(145.82M)
Operating Margin—————
Interest Income0072K8.46M11.34M
Interest Expense00000
Other Income / Expenses0072K8.18M11.78M
Income Before Tax(43.36K)(3.52K)(64.7M)(74.28M)(134.04M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.36K)(3.52K)(64.7M)(74.28M)(134.04M)
Net Margin—————
EPS (Basic)(0.00)0.00(3.16)0.46(4.30)
EPS (Diluted)(0.00)(0.00)(3.16)0.46(4.30)
Weighted Avg Shares20.49M20.49M20.49M16.64M31.14M
Weighted Avg Shares (Diluted)20.49M20.49M20.49M16.64M31.14M

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.